Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins

Journal of Infection

Volumn 57, Issue 1, 2008, Pages 78-81

  Bonora, S ^a   Mondo, A ^a   Trentini, L ^a   Calcagno, A ^a   Lucchini, A ^a   Di Perri, G ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

HIV infection; Moxifloxacin; Tuberculosis

Indexed keywords

ABACAVIR; ANTIHISTAMINIC AGENT; CORTICOSTEROID; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METRONIDAZOLE; MOXIFLOXACIN; PREDNISONE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; STREPTOMYCIN; TENOFOVIR; TICLOPIDINE; VIRUS RNA;

ABSENCE OF SIDE EFFECTS; ADULT; ARTERY DISEASE; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG ERUPTION; DRUG FEVER; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYSICAL EXAMINATION; SIDE EFFECT; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DRUG RESISTANCE, BACTERIAL; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; RIFAMYCINS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 46149124746     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.05.005     Document Type: Article

References (19)

1. Di Perri G., Aguilar Marucco D., Mondo A., Gonzalez de Requena D., Audagnotto S., Gobbi F., et al. Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy. Expert Opin Drug Saf 4 (2005) 821-836
2. Pozniak A.L., Miller R.F., Lipman M.C., Freedman A.R., Ormerod L.P., Johnson M.A., et al. BHIVA Guidelines Writing Committee BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005. HIV Med 6 Suppl. 2 (2005) 62-83
3. Gosling R.D., Uiso L.O., Sam N.E., Bongard E., Kanduma E.G., Nyindo M., et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 168 (2003) 1342-1345
4. Codecasa L.R., Ferrara G., Ferrarese M., Morandi M.A., Penati V., Lacchini C., et al. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir Med 100 (2006) 1566-1572
5. Bayer Schering Pharma. Direct Healthcare Professional Communication regarding moxifloxacin and serious hepatic and bullous skin reaction. Available from: (February 2008). www.mhra.gov.uk [accessed on 08.05.08]
6. Rodvold K.A., and Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 21 (2001) 233S-252S
7. Breen R.A., Swaden L., Ballinger J., and Lipman M.C. Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs 66 (2006) 2299-2308
8. Rodriguez J.C., Ruiz M., Lopez M., and Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 20 (2002) 464-467
9. Gillespie S.H., and Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 44 (1999) 393-395
10. Nuermberger E.L., Yoshimatsu T., Tyagi S., O′Brien R.J., Vernon A.N., Chaisson R.E., et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169 (2004) 421-426
11. Nuermberger E.L., Yoshimatsu T., Tyagi S., Williams K., Rosenthal I., O′Brien R.J., et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170 (2004) 1131-1134
12. Valerio G., Bracciale P., Manisco V., Quitadamo M., Legari G., and Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 15 (2003) 66-70
13. Pletz M.W., De Roux A., Roth A., Neumann K.H., Mauch H., and Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 48 (2004) 780-782
14. Gillespie S.H., Gosling R.D., Uiso L., Sam N.E., Kanduma E.G., and McHugh T.D. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. J Antimicrob Chemother 56 (2005) 1169-1171
15. Burman W.J., Goldberg S., Johnson J.L., Muzanye G., Engle M., Mosher A.W., et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174 (2006) 331-338
16. Kubendiran G., Paramasivan C.N., Sulochana S., and Mitchison D.A. Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. J Chemother 18 (2006) 617-623
17. Hu Y., Coates A.R., and Mitchison D.A. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 47 (2003) 653-657
18. Di Perri G., and Bonora S. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?. J Antimicrob Chemother 54 (2004) 593-602
19. Pollock R.C., Shanson D.C., Nelson M., Neild P.J., and Gazzard B.G. Clostridium difficile diarrhoea and rifabutin. Lancet 343 (1994) 922